Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 22Neoplasms 15Pulmonary Embolism 10Venous Thrombosis 9Thrombosis 6Multiple Myeloma 4Upper Extremity Deep Vein Thrombosis 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoma 2Intracranial Thrombosis 2Hematologic Neoplasms 2Carcinoma, Hepatocellular 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thromboprophylaxis 1Thromboembolism 1Thrombocytopenia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Mesenteric Ischemia 1Leukemia 1Head and Neck Neoplasms 1

Interventions

apixaban 1Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesenteric Ischemia × apixaban × Clear all
NCT02585713 2020-08-04

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

Phase 3 Completed
300 enrolled 11 charts
Classical hematology

Neoplasm Metastasis, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Intracranial Thrombosis, Venous Thromboembolism, Mesenteric Ischemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡